Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caplacizumab plus immunosuppressive therapy without first-line plasma exchange in adults with immune-mediated thrombotic thrombocytopenic purpura
NL-OMON59307Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2023
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of caplacizumab in thrombotic thrombocytopenic purpura (TTP), sponsored by Sanofi. Primary endpoint: Remission without therapeutic plasma exchange. Started Dec 2023; status: completed.
02
Drugs
caplacizumab
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on NL-OMON59307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59307.